Overgrowth syndromes are rare genetic disorders defined by tissue hypertrophy that can be either localized or generalized, affecting both latitudinal and longitudinal growth. The genes involved in overgrowth syndromes are not well characterized but mostly concern the PIK3CA/AKT/mTOR pathway, a major actor of cell growth and proliferation. The mutations are not inherited but occurs during embryogenesis leading to somatic mosaicism. Owing to the variability of the clinical presentation, their exact prevalence is yet unknown. In order to answer this question, the investigators team create here the first French national registry on overgrowth syndromes.
Overgrowth syndromes are rare genetic disorders defined by tissue hypertrophy that can be either localized or generalized, affecting both latitudinal and longitudinal growth. The genes involved in overgrowth syndromes are not well characterized but mostly concern the PIK3CA/AKT/mTOR pathway, a major actor of cell growth and proliferation. The mutations are not inherited but occurs during embryogenesis leading to somatic mosaicism. Owing to the variability of the clinical presentation, their exact prevalence is yet unknown. In order to answer this question, the investigators team create here the first French national registry on overgrowth syndromes.
Study Type
OBSERVATIONAL
Enrollment
2,500
The investigators will collect demographic, clinical, biological and imaging characteristics of patients with PROS.
Translational medicine and Targeted therapies unit, Hôpital Necker Enfants Malades
Paris, France
RECRUITINGDescription of patients with overgrowth syndromes
Clinical and molecular characterization of patients with overgrowth syndromes will be performed.
Time frame: 5 years
Prevalence of overgrowth syndromes in France
An estimation of the prevalence of overgrowth syndromes in France will be done
Time frame: 5 years
Biobanking of samples derived from patients with overgrowth syndromes
A biobank will be created with biological samples (plasma) collected for research and residual biological samples from patient cares (treatment/diagnosis)
Time frame: 5 years
Description of patient cares: mumber of consultations and hospitalizations, number of treatment lines, grouping of patients by type of course (clusters)
An analysis of care trajectories will be performed. These data will be collected from health insurance databases for patients with overgrowth syndromes.
Time frame: 5 years
Economic evaluation of cares for patients with overgrowth syndromes: cost of care, per period and cumulative.
SDNS data will be used to estimate care costs per year for patients with overgrowth syndrome.
Time frame: 5 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.